% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Stegmayr:874448,
      author       = {Stegmayr, Carina and Stoffels, Gabriele and Filß,
                      Christian and Heinzel, Alexander and Lohmann, Philipp and
                      Willuweit, Antje and Ermert, Johannes and Coenen, Heinrich
                      Hubert and Mottaghy, Felix M. and Galldiks, Norbert and
                      Langen, Karl-Josef},
      title        = {{C}urrent trends in the use of
                      {O}-(2-[18{F}]fluoroethyl)-{L}-tyrosine ([18{F}]{FET}) in
                      neurooncology},
      journal      = {Nuclear medicine and biology},
      volume       = {92},
      issn         = {0969-8051},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {FZJ-2020-01449},
      pages        = {78-84},
      year         = {2021},
      abstract     = {The diagnostic potential of PET using the amino acid
                      analogue O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in
                      brain tumor diagnostics has been proven in many studies
                      during the last two decades and is still the subject of
                      multiple studies every year. In addition to standard
                      magnetic resonance imaging (MRI), positron emission
                      tomography (PET) using [18F]FET provides important
                      diagnostic data concerning brain tumor delineation, therapy
                      planning, treatment monitoring, and improved differentiation
                      between treatment-related changes and tumor recurrence. The
                      pharmacokinetics, uptake mechanisms and metabolism have been
                      well described in various preclinical studies. The
                      accumulation of [18F]FET in most benign lesions and healthy
                      brain tissue has been shown to be low, thus providing a high
                      contrast between tumor tissue and benign tissue alterations.
                      Based on logistic advantages of F-18 labelling and
                      convincing clinical results, [18F]FET has widely replaced
                      short lived amino acid tracers such as
                      L-[11C]methyl-methionine ([11C]MET) in many centers across
                      Western Europe. This review summarizes the basic knowledge
                      on [18F]FET and its contribution to the care of patients
                      with brain tumors. In particular, recent studies about
                      specificity, possible pitfalls, and the utility of [18F]FET
                      PET in tumor grading and prognostication regarding the
                      revised WHO classification of brain tumors are addressed.},
      cin          = {INM-3 / INM-4 / INM-5},
      ddc          = {570},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      I:(DE-Juel1)INM-5-20090406},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {32113820},
      UT           = {WOS:000616652500010},
      doi          = {10.1016/j.nucmedbio.2020.02.006},
      url          = {https://juser.fz-juelich.de/record/874448},
}